Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.
2.

PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outs.

Olaussen KA, Adam J, Vanhecke E, Vielh P, Pirker R, Friboulet L, Popper H, Robin A, Commo F, Thomale J, Kayitalire L, Filipits M, Le Chevalier T, André F, Brambilla E, Soria JC.

Lung Cancer. 2013 May;80(2):216-22. doi: 10.1016/j.lungcan.2013.01.014.

PMID:
23410825
3.
4.

ERCC1, MLH1, MSH2, MSH6, and βIII-tubulin: resistance proteins associated with response and outcome to platinum-based chemotherapy in malignant pleural mesothelioma.

Ting S, Mairinger FD, Hager T, Welter S, Eberhardt WE, Wohlschlaeger J, Schmid KW, Christoph DC.

Clin Lung Cancer. 2013 Sep;14(5):558-567.e3. doi: 10.1016/j.cllc.2013.04.013.

PMID:
23810210
5.

ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy.

Hwang IG, Ahn MJ, Park BB, Ahn YC, Han J, Lee S, Kim J, Shim YM, Ahn JS, Park K.

Cancer. 2008 Sep 15;113(6):1379-86. doi: 10.1002/cncr.23693.

6.
7.

[Prognostic significance of ERCC1 mRNA expression in patients with non-small cell lung cancer receiving platinum-based chemotherapy].

Qian XP, Liu BR, Shi MQ, Liu XZ, Hu WJ, Zou ZY, Wei J.

Zhonghua Zhong Liu Za Zhi. 2009 Jan;31(1):33-7. Chinese.

PMID:
19538866
8.

DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.

Olaussen KA, Dunant A, Fouret P, Brambilla E, André F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, Stahel R, Sabatier L, Pignon JP, Tursz T, Le Chevalier T, Soria JC; IALT Bio Investigators..

N Engl J Med. 2006 Sep 7;355(10):983-91.

9.

Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.

Azuma K, Sasada T, Kawahara A, Takamori S, Hattori S, Ikeda J, Itoh K, Yamada A, Kage M, Kuwano M, Aizawa H.

Lung Cancer. 2009 Jun;64(3):326-33. doi: 10.1016/j.lungcan.2008.09.002.

PMID:
18977553
10.

Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy.

Ota S, Ishii G, Goto K, Kubota K, Kim YH, Kojika M, Murata Y, Yamazaki M, Nishiwaki Y, Eguchi K, Ochiai A.

Lung Cancer. 2009 Apr;64(1):98-104. doi: 10.1016/j.lungcan.2008.07.014.

PMID:
18823676
11.

Excision-repair-cross-complement-1 protein as a prognostic factor in patients with advanced non-small cell lung cancer treated with platinum-based first-line chemotherapy.

Vassalou H, Stathopoulos E, Fiolitaki G, Koutsopoulos A, Voutsina A, Georgoulias V, Mavroudis D.

Lung Cancer. 2013 Nov;82(2):324-9. doi: 10.1016/j.lungcan.2013.08.001.

PMID:
23993732
12.

Cisplatin benefit is predicted by immunohistochemical analysis of DNA repair proteins in squamous cell carcinoma but not adenocarcinoma: theranostic modeling by NSCLC constituent histological subclasses.

Pierceall WE, Olaussen KA, Rousseau V, Brambilla E, Sprott KM, Andre F, Pignon JP, Le Chevalier T, Pirker R, Jiang C, Filipits M, Chen Y, Kutok JL, Weaver DT, Ward BE, Soria JC.

Ann Oncol. 2012 Sep;23(9):2245-52. doi: 10.1093/annonc/mdr624.

13.

ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial.

Vilmar AC, Santoni-Rugiu E, Sørensen JB.

Ann Oncol. 2010 Sep;21(9):1817-24. doi: 10.1093/annonc/mdq053.

14.

Hypoxia-inducible factor-1α and excision repair cross-complementing 1 in patients with small cell lung cancer who received front-line platinum-based chemotherapy: a retrospective study.

Lee GW, Go SI, Cho YJ, Jeong YY, Kim HC, Duk Lee J, Hwang YS, Ko GH, Lee JH, Kim DC, Yang JW, Oh S, Lee JS.

J Thorac Oncol. 2012 Mar;7(3):528-34. doi: 10.1097/JTO.0b013e3182417830.

15.
16.
17.

RRM1 and ERCC1 expression in peripheral blood versus tumor tissue in gemcitabine/carboplatin-treated advanced non-small cell lung cancer.

Zhang GB, Chen J, Wang LR, Li J, Li MW, Xu N, Wang Y, Shentu JZ.

Cancer Chemother Pharmacol. 2012 May;69(5):1277-87. doi: 10.1007/s00280-012-1834-x.

PMID:
22302408
18.

Prognostic and predictive role of ERCC1 protein expression in locally advanced stage III non-small cell lung cancer.

Sad LM, Younis SG, Elity MM.

Med Oncol. 2014 Jul;31(7):58. doi: 10.1007/s12032-014-0058-9.

PMID:
24935625
19.

Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma--a randomized phase II trial.

Hsu C, Kuo SH, Hu FC, Cheng AL, Shih JY, Yu CJ, Lin CC, Huang TC, Yang PC, Yang CH.

Lung Cancer. 2008 Dec;62(3):334-43. doi: 10.1016/j.lungcan.2008.03.010.

PMID:
18450322
20.

Expression of excision repair cross-complementation group 1 protein predicts poor outcome in advanced non-small cell lung cancer patients treated with platinum-based doublet chemotherapy.

Lee HW, Choi YW, Han JH, Kim JH, Jung JH, Jeong SH, Kang SY, Choi JH, Oh YT, Park KJ, Hwang SC, Sheen SS.

Lung Cancer. 2009 Sep;65(3):377-82. doi: 10.1016/j.lungcan.2008.12.005.

PMID:
19150580
Items per page

Supplemental Content

Support Center